In quest to meet user fee goals, FDA’s performance continues downward trend
A recent update to the FDA’s running tally of how it’s meeting its user fee-related performance goals during the pandemic shows an agency that is not out of the woods yet.
The latest numbers reveal that for a second straight quarter in 2021, the FDA has met its user fee goal dates for 93% of original new drug applications, which compares with 94% and 98% for the previous two quarters in 2020, respectively.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.